Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease.
Alzheimer's disease (AD) is a complex, progressive, neurodegenerative disorder. As with other common chronic diseases, multiple risk factors contribute to the onset and progression of AD. Many researchers have evaluated the epidemiologic and pathophysiological association between AD, cardiovascular diseases (CVDs), and cerebrovascular diseases (CBVDs), including commonly reported risk factors such as diabetes, hypertension, and dyslipidemia. Relevant therapies of CVDs/CBVDs for the attenuation of AD have also been empirically investigated. Considering the challenges of new drug development, in terms of cost and time, multifactorial approaches such as therapeutic repositioning of CVD/CBVD medication should be explored to delay the onset and progression of AD. Thus, in this review, we discuss our current understanding of the association between cardiovascular risk factors and AD, as revealed by clinical and non-clinical studies, as well as the therapeutic implications of CVD/CBVD medication that may attenuate AD. Furthermore, we discuss future directions by evaluating ongoing trials in the field.
['Lee|Heeyoung|H|', 'Kim|EunYoung|E|http://orcid.org/0000-0003-3525-8805']
D000544:Alzheimer Disease D002317:Cardiovascular Agents D002318:Cardiovascular Diseases D002561:Cerebrovascular Disorders D002986:Clinical Trials as Topic D003920:Diabetes Mellitus D018450:Disease Progression D058492:Drug Repositioning D050171:Dyslipidemias D000082742:Heart Disease Risk Factors D006801:Humans D007004:Hypoglycemic Agents D018696:Neuroprotective Agents
Cerebrovascular disease Alzheimer's disease Cardiovascular disease Drug repositioning Pharmacotherapeutic implications